Scalper1 News
Shares of Gilead Sciences (GILD) hit a new high near 113 in the stock market today as the biotech prepared to deliver its Q3 report after the close Tuesday, while an analyst noted that a couple of its potential competitors seemed to be faltering. Analysts polled by Thomson Reuters expect the company to report earnings of $1.92 a share, up 269% from the year-earlier quarter. Sales were estimated at just under $6 billion, up 115% from last year’s Scalper1 News
Scalper1 News